Interim report April-June 2020
Gothenburg, August 26, 2020 - Vicore Pharma Holding AB (publ) publishes the interim report for the second quarter 2020.Important events during the second quarter · In April, Vicore Pharma gained approval from the UK regulatory agency MHRA, to start the phase II study with VP01 on patients with COVID-19. The ATTRACT study is a randomized, double blind, placebo controlled study in approximately 100 COVID-19 patients with a moderately severe disease, treated with basic respiratory care, but not on mechanical ventilation. The study will investigate the efficacy on respiratory failure and